143 related articles for article (PubMed ID: 11378562)
41. High anti-lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG).
Weide R; Hess G; Köppler H; Heymanns J; Thomalla J; Aldaoud A; Losem C; Schmitz S; Haak U; Huber C; Unterhalt M; Hiddemann W; Dreyling M;
Leuk Lymphoma; 2007 Jul; 48(7):1299-306. PubMed ID: 17613757
[TBL] [Abstract][Full Text] [Related]
42. Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial.
Coiffier B; Osmanov EA; Hong X; Scheliga A; Mayer J; Offner F; Rule S; Teixeira A; Walewski J; de Vos S; Crump M; Shpilberg O; Esseltine DL; Zhu E; Enny C; Theocharous P; van de Velde H; Elsayed YA; Zinzani PL;
Lancet Oncol; 2011 Aug; 12(8):773-84. PubMed ID: 21724462
[TBL] [Abstract][Full Text] [Related]
43. Immunotherapy with rituximab following high-dose therapy and autologous stem-cell transplantation for mantle cell lymphoma.
Mangel J; Buckstein R; Imrie K; Spaner D; Crump M; Tompkins K; Reis M; Perez-Ordonez B; Deodhare S; Romans R; Pennell N; Robinson JB; Hewitt K; Richardson P; Lima A; Pavlin P; Berinstein NL
Semin Oncol; 2002 Feb; 29(1 Suppl 2):56-69. PubMed ID: 11842390
[TBL] [Abstract][Full Text] [Related]
44. Rituximab plus short-duration chemotherapy as first-line treatment for follicular non-Hodgkin's lymphoma: a phase II trial of the minnie pearl cancer research network.
Hainsworth JD; Litchy S; Morrissey LH; Andrews MB; Grimaldi M; McCarty M; Greco FA
J Clin Oncol; 2005 Mar; 23(7):1500-6. PubMed ID: 15632411
[TBL] [Abstract][Full Text] [Related]
45. Anti-idiotype antibodies can induce long-term complete remissions in non-Hodgkin's lymphoma without eradicating the malignant clone.
Davis TA; Maloney DG; Czerwinski DK; Liles TM; Levy R
Blood; 1998 Aug; 92(4):1184-90. PubMed ID: 9694706
[TBL] [Abstract][Full Text] [Related]
46. Radioimmunotherapy in follicular lymphoma.
Illidge T; Morschhauser F
Best Pract Res Clin Haematol; 2011 Jun; 24(2):279-93. PubMed ID: 21658624
[TBL] [Abstract][Full Text] [Related]
47. Optimization of postremission therapy in follicular lymphoma: efficacy of rituximab maintenance.
Roy R; Gordon LI
J Natl Compr Canc Netw; 2011 May; 9(5):563-71. PubMed ID: 21550969
[TBL] [Abstract][Full Text] [Related]
48. Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98.
Martinelli G; Schmitz SF; Utiger U; Cerny T; Hess U; Bassi S; Okkinga E; Stupp R; Stahel R; Heizmann M; Vorobiof D; Lohri A; Dietrich PY; Zucca E; Ghielmini M
J Clin Oncol; 2010 Oct; 28(29):4480-4. PubMed ID: 20697092
[TBL] [Abstract][Full Text] [Related]
49. Cost-effectiveness of extended adjuvant rituximab for US patients aged 65-70 years with follicular lymphoma in second remission.
Hayslip JW; Simpson KN
Clin Lymphoma Myeloma; 2008 Jun; 8(3):166-70. PubMed ID: 18650180
[TBL] [Abstract][Full Text] [Related]
50. Follicular lymphoma: 2014 update on diagnosis and management.
Freedman A
Am J Hematol; 2014 Apr; 89(4):429-36. PubMed ID: 24687887
[TBL] [Abstract][Full Text] [Related]
51. Successful treatment of isolated cutaneous relapse of follicular lymphoma with rituximab.
Ferrer A; López-Guillermo A; Montoto S; Estrach T; Colomo L; Montserrat E
Ann Hematol; 2001 Aug; 80(8):479-81. PubMed ID: 11563595
[TBL] [Abstract][Full Text] [Related]
52. Should all patients with indolent lymphoma be treated with rituximab maintenance therapy? An overview of the data.
Andemariam B; Leonard JP
Clin Lymphoma Myeloma; 2006 Oct; 7 Suppl 1():S20-3. PubMed ID: 17101069
[TBL] [Abstract][Full Text] [Related]
53. Rituximab purging and maintenance combined with auto-SCT: long-term molecular remissions and prolonged hypogammaglobulinemia in relapsed follicular lymphoma.
Hicks LK; Woods A; Buckstein R; Mangel J; Pennell N; Zhang L; Imrie K; Spaner D; Cheung MC; Boudreau A; Reis M; Crump M; Berinstein NL
Bone Marrow Transplant; 2009 May; 43(9):701-8. PubMed ID: 19029963
[TBL] [Abstract][Full Text] [Related]
54. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule.
Ghielmini M; Schmitz SF; Cogliatti SB; Pichert G; Hummerjohann J; Waltzer U; Fey MF; Betticher DC; Martinelli G; Peccatori F; Hess U; Zucca E; Stupp R; Kovacsovics T; Helg C; Lohri A; Bargetzi M; Vorobiof D; Cerny T
Blood; 2004 Jun; 103(12):4416-23. PubMed ID: 14976046
[TBL] [Abstract][Full Text] [Related]
55. Quantitative real-time polymerase chain reaction for monitoring minimal residual disease in patients with advanced indolent lymphomas treated with rituximab, fludarabine, mitoxantrone, and dexamethasone.
Sarris AH; Jiang Y; Tsimberidou AM; Thomaides A; Rassidakis GZ; Ford RJ; Medeiros LJ; Cabanillas F; McLaughlin P
Semin Oncol; 2002 Feb; 29(1 Suppl 2):48-55. PubMed ID: 11842389
[TBL] [Abstract][Full Text] [Related]
56. Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma.
Vose JM; Link BK; Grossbard ML; Czuczman M; Grillo-Lopez A; Gilman P; Lowe A; Kunkel LA; Fisher RI
J Clin Oncol; 2001 Jan; 19(2):389-97. PubMed ID: 11208830
[TBL] [Abstract][Full Text] [Related]
57. Follicular lymphoma: 2012 update on diagnosis and management.
Freedman A
Am J Hematol; 2012 Oct; 87(10):988-95. PubMed ID: 23001911
[TBL] [Abstract][Full Text] [Related]
58. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy.
Czuczman MS; Grillo-López AJ; White CA; Saleh M; Gordon L; LoBuglio AF; Jonas C; Klippenstein D; Dallaire B; Varns C
J Clin Oncol; 1999 Jan; 17(1):268-76. PubMed ID: 10458242
[TBL] [Abstract][Full Text] [Related]
59. Clinical activity and safety of combination immunotherapy with IFN-alpha 2a and Rituximab in patients with relapsed low grade non-Hodgkin's lymphoma.
Sacchi S; Federico M; Vitolo U; Boccomini C; Vallisa D; Baldini L; Petrini M; Rupoli S; Di Raimondo F; Merli F; Liso V; Tabilio A; Saglio G; Vinci G; Brugiatelli M; Dastoli G;
Haematologica; 2001 Sep; 86(9):951-8. PubMed ID: 11532623
[TBL] [Abstract][Full Text] [Related]
60. Consensus conference: implementing treatment recommendations on yttrium-90 immunotherapy in clinical practice - report of a European workshop.
Zinzani PL; d'Amore F; Bombardieri E; Brammer C; Codina JG; Illidge T; Jurczak W; Linkesch W; Morschhauser F; Vandenberghe E; Van Hoof A
Eur J Cancer; 2008 Feb; 44(3):366-73. PubMed ID: 18194857
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]